Literature DB >> 2100512

[The treatment of imported Plasmodium falciparum malaria with halofantrine. Apropos of 59 case reports (corrected and republished article orginally printed in Med Trop (Mars) 1990 Jan-Mar;50(1):113-7)].

J Bernard1, J Sarrouy, I Dupasquier, J L Lesbordes, M Gimenez, L Geffray, J M Becker, J M Molinas, G Jourdan.   

Abstract

59 cases of Plasmodium falciparum malaria fever occurring in non-immune Caucasian subjects having got a correct chemoprophylaxis by chloroquine were treated by halofantrine (HALFAN). They were given 1500 mg divided in 3 doses of 500 mg every 6 hours from D1 to D8. All them were back from a malarial highly endemic zone with chloroquine resistance. Analysis of the main biological and clinical efficiency parameters displayed very satisfactory results: disappearances of fever (mean 22 H) and parasitemia (mean 36 H) are short. After two months of monitoring, no malaria recrudescence was noted. With an efficacy of 10 p.c. associated to a noticeable clinical and biological tolerance Halofantrine is a first-class treatment of chloroquine resistant malaria fever.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2100512

Source DB:  PubMed          Journal:  Med Trop (Mars)        ISSN: 0025-682X


  3 in total

Review 1.  Halofantrine: a new substance for treatment of multidrug-resistant malaria.

Authors:  H D Nothdurft; R Clemens; H L Bock; T Löscher
Journal:  Clin Investig       Date:  1993-01

Review 2.  Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; K L Goa
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of halofantrine.

Authors:  J Karbwang; K Na Bangchang
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.